Indication CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).
CINRYZE is the first C1 esterase inhibitor (C1-INH) approved by the FDA for routine prophylaxis of hereditary angioedema (HAE) attacks in adults, adolescents, and pediatric patients (6 years of age and older).
CINRYZE has been available since 2008 for adolescents and adults. More than 1,000 physicians have prescribed CINRYZE to more than 2,000 patients, resulting in over 709,000 distributed doses.*2
*Figures current as of June 2016
CINRYZE increases plasma levels of C1-inhibitor activity and helps prevent HAE attacks1
CINRYZE addresses the deficiency or dysfunction of C1-INH. CINRYZE can reduce vascular permeability by preventing the generation of bradykinin.1,3
How CINRYZE® (C1 esterase inhibitor [human]) works1,3,4
(Swipe image to view more)
Learn more about how CINRYZE replaces missing functional C1 esterase inhibitor in the body.1
How CINRYZE Works Douglas T. Johnston, D.O., FAAAAI, FACAAI
Contraindications: CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.
Hypersensitivity Reactions: Severe hypersensitivity reactions may occur during or after administration of CINRYZE. Consider treatment methods carefully, because hypersensitivity reactions may have symptoms similar to HAE attacks. In case of hypersensitivity, discontinue CINRYZE infusion and institute appropriate treatment. Have epinephrine immediately available for treatment of an acute severe hypersensitivity reaction.
Thromboembolic Events: Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 Esterase Inhibitor (Human) products, including CINRYZE, following administration in patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives, certain androgens, morbid obesity, and immobility. Benefits of CINRYZE for routine prophylaxis of HAE attacks should be weighed against the risks of TE events in patients with underlying risk factors. Monitor patients with known risk factors for TE events during and after CINRYZE administration.
Transmissible Infectious Agents: Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ALL infections thought by a physician possibly to have been transmitted by CINRYZE should be reported to Shire Medical Information at 1-800-828-2088.
Adverse Reactions: The only serious adverse reaction observed in clinical studies of CINRYZE was cerebrovascular accident. The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever. Post marketing adverse reactions include local infusion site reactions and hypersensitivity. Post marketing thromboembolic events have been reported, including catheter-related and deep venous thromboses, transient ischemic attack, and stroke.
Please click here for Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Shire Medical Information at 1-800-828-2088 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.